MARKET

MNOV

MNOV

Medicinova
NASDAQ
1.250
+0.020
+1.63%
After Hours: 1.270 +0.02 +1.60% 18:20 06/15 EDT
OPEN
1.270
PREV CLOSE
1.230
HIGH
1.280
LOW
1.220
VOLUME
122.09K
TURNOVER
--
52 WEEK HIGH
1.960
52 WEEK LOW
1.168
MARKET CAP
61.53M
P/E (TTM)
-5.2367
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MNOV last week (0608-0612)?
Weekly Report · 20h ago
MediciNova Receives U.S. Patent Office Notice Of Allowance Covering The Use Of Ibudilast In The Treatment Of Glioblastoma
Benzinga · 06/08 12:07
MEDICINOVA - PATENT EXPECTED TO EXPIRE NO EARLIER THAN SEPTEMBER 2042
Reuters · 06/08 12:06
Weekly Report: what happened at MNOV last week (0601-0605)?
Weekly Report · 06/08 09:49
Weekly Report: what happened at MNOV last week (0525-0529)?
Weekly Report · 06/01 09:52
Analysts’ Top Healthcare Picks: Coherus Biosciences (CHRS), Medicinova (MNOV)
TipRanks · 05/28 19:20
Analyst Initiates Buy on MediciNova, Citing Pivotal Tipelukast and Ibudilast Catalysts to Support $10 Price Target
TipRanks · 05/28 07:55
MediciNova Concludes Phase 2 For MN-001 In Treating Diabetic Non-Alcoholic Fatty Liver Disease
NASDAQ · 05/27 08:46
More
About MNOV
MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.

Webull offers Medicinova Inc stock information, including NASDAQ: MNOV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNOV stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MNOV stock methods without spending real money on the virtual paper trading platform.